

HHS Public Access

Author manuscript *Eur J Neurosci*. Author manuscript; available in PMC 2020 May 01.

Published in final edited form as:

Eur J Neurosci. 2019 May ; 49(9): 1084–1090. doi:10.1111/ejn.14304.

Muscle Ciliary Neurotrophic Factor Receptor a Contributes to Motor Neuron STAT3 Activation Following Peripheral Nerve Lesion

Nancy Lee¹, Rachel P. Spearry¹, Carolyn E. Rydyznski¹, and A. John MacLennan¹

¹Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, Ohio, USA, 45267-0576

Abstract

Expression of the ciliary neurotrophic factor (CNTF) receptor essential ligand binding subunit, CNTF receptor a (CNTFRa), is induced in motor neurons and skeletal muscle following peripheral nerve lesion. We previously found muscle CNTFRa promotes motor neuron axon regeneration post-lesion. Both nerve lesion and CNTF administration activate motor neuron signal transducer and activator of transcription 3 (STAT3), a transcription factor implicated in axon growth, suggesting CNTF receptors may contribute to the lesion-induced STAT3 activation. However, many receptor types signal through STAT3, and if CNTF receptors contribute, motor neuron receptors seemed most likely to regulate motor neuron STAT3. To determine the role played by muscle CNTFRa, we used *in vivo*, muscle-specific CNTFRa depletion in mice and report here that this selectively impairs the second phase, sustained motor neuron STAT3 activation post-lesion. Thus, muscle CNTFRa makes an essential contribution to motor neuron STAT3 activation during axon regeneration and may thereby promote axon regeneration through such signaling. We also report CNTFRa quantitative PCR suggesting involvement of many denervated muscle types, as well as muscle damaged at the lesion site. The present data add to the evidence suggesting that enhancing muscle CNTFRa expression may promote motor neuron regeneration in trauma and disease.

Graphical Abstract

Using muscle-specific CNTFRa gene disruption and the mouse sciatic nerve crush model, this study shows muscle CNTFRa contributes to the pSTAT3 response in lesion motor neurons. Image shows pSTAT3 immunohistochemistry of spinal cord ventral horns from control (A,B) and CNTFRa-knockdown (C,D) mice with lesioned side on right (B,D).

Conflict of interest: The authors declare no conflicts.

Correspondence: A. John MacLennan, Pharmacology and Systems Physiology, 231 Albert Sabin Way, University of Cincinnati, Cincinnati, Ohio, USA, 45267-0576; john.maclen@uc.edu; Phone: 513-558-0667.

Author contributions: Study concept and design: AJM. Data acquisition: NL, RPS, CER. Data analysis/interpretation: NL, AJM. Drafting manuscript: AJM. Reviewing and editing manuscript: NL, RPS, CER.

Data accessibility statement: All data generated or analyzed during this study are included in this published article.

Keywords

mouse; sciatic nerve; mlc1f-Cre; regeneration

INTRODUCTION

CNTF receptors contain CNTFRa, leukemia inhibitory factor receptor β (LIFR β) and gp130 (Davis *et al.*, 1993a). Unlike LIFR β and gp130, CNTFRa is unique to CNTF receptors and required for all CNTF receptor signaling (Davis *et al.*, 1993a; Elson *et al.*, 2000). Therefore, CNTFRa disruption best reveals endogenous CNTF receptor function. Unconditional CNTFRa knockout mice die perinatally with motor neuron (MN) loss (DeChiara *et al.*, 1995), precluding adult studies needed to identify neuroregenerative mechanisms to target in adult MN diseases and neurotrauma.

Adult MNs survive and regenerate axons following nerve crush (e.g., Lee *et al.*, 2013), and are therefore used to identify mechanisms supporting adult MN maintenance and axon regeneration. Indirect data suggest CNTF receptor involvement. Neuromuscular CNTFRa expression is restricted to MNs and skeletal muscle (MacLennan *et al.*, 1996; Lee *et al.*, 1997) and nerve crush increases expression in both cell types during axon regeneration (Davis *et al.*, 1993b; Helgren *et al.*, 1994; MacLennan *et al.*, 1999). CNTF administration accelerates post-lesion axonal regeneration (Sahenk *et al.*, 1994).

Moreover, CNTF administration and nerve lesion both activate MN STAT3 through Tyr705 phosphorylation (MacLennan *et al.*, 2000; Kirsch *et al.*, 2003; Lee *et al.*, 2004) and phospho-Tyr705 STAT3 (pSTAT3) activation promotes axon growth (Shin *et al.*, 2012; Pernet *et al.*, 2013; Luo *et al.*, 2016). However, many receptor types signal through STAT3 (Levy and Darnell, 2002). Therefore, it was not known whether CNTF receptors contribute to STAT3 activation in regenerating MNs. Moreover, it seemed most likely that if they did contribute to MN STAT3 activation, involvement would be limited to MN CNTF receptors.

In the studies here, muscle-specific *in vivo* gene disruption and pSTAT3 immunohistochemistry were used to directly determine the contribution of muscle CNTFRa to post-lesion MN STAT3 activation. The work also includes CNTFRa quantitative real-time PCR (qRT-PCR) to access the potential involvement of different classes of denervated muscles, as well as muscle damaged at the lesion site.

MATERIALS and METHODS

Floxed CNTFRa (Lee *et al.*, 2008) and mlc1f-Cre (Bothe *et al.*, 2000; from Dr. Steven Burden [NYU]) mice were genotyped by tail biopsy PCR and maintained on a 129SvEvBrd background. CNTFRa-depleted/knockdown mice (mlc1f-Cre^{+/-}/flxCNTFRa^{+/+}) and nonfloxed littermate controls (mlc1f-Cre^{+/-}/flxCNTFRa^{-/-}) were generated by mlc1f-Cre^{+/-/} flxCNTFRa+/- X mlc1f-Cre^{-/-/}flxCNTFRa+/- breeding (both sexes; 2.5–4 months old; housed 4/pressurized individually ventilated cage) and processed in parallel (blind to genotype) through all procedures (total mice used in experiments=37).

For the unilateral sciatic nerve crush, mice were anesthetized with 100 mg/kg ketamine; 20 mg/kg xylazine. Mid-thigh skin was opened and a 5 mm longitudinal cut in the biceps femoris exposed the underlying nerve which was freed from surrounding connective tissue where it passes superficial to the tendon of the obturator internus. The nerve was crushed for 10 seconds with Dumont #5 Biologic Tip forceps (Fine Science Tools). The biceps femoris muscle and overlying skin were then closed with 4–0 suture. The mice were then monitored until completely recovered from anesthetic, and daily thereafter.

University of Cincinnati IACUC approved all procedures (06–09-04–01) as conducted in accordance with U.S. NIH/OLAW regulations.

Statistics:

In each pSTAT3 immunohistochemistry experiment Student's t-tests were used to compare the knockdown and littermate control mice. For each CNTFRa qRT-PCR analyses, an ANOVA was conducted to evaluate the main effects of knockdown and lesion. All statistics performed with GraphPad Prism 5 software.

TaqMan CNTFRa qRT-PCR (GAPDH normalization) was performed with an Applied Biosystems StepOnePlus Real-Time PCR system and ThermoFisher primers (CNTFRa; cat.#4331182 [Mm00516693_m1], GAPDH; cat.# 4331182 [Mm99999915_g1]).

Following overdose with avertin (20 mg/ml; IP), mice were perfused with 4°C saline and then 4°C 4% paraformaldehyde. Spinal cords were post-fixed in 4% paraformaldehyde overnight at 4°C and then cryoprotected for at least 48 hours in 30% sucrose with 2.5mM sodium azide before sectioning. Every sixth 30um coronal cryostat section was collected throughout the complete L5 cord, which contains the sciatic nerve projecting MNs (Janjua and Leong, 1984), and processed slide mounted with previously described immunohistochemistry details (Lee *et al.*, 2004) using an antiserum (1:1,000) specifically recognizing Tyr705-phosphorylated STAT3 (Cell Signaling Technology; #9131), ABC amplification (Vector Laboratories; #PK-6100) and cyanine-3 tyramide (Perkin Elmer; #SAT704B).

Individuals *unaware of genotype* stereologically quantified (Hyman *et al.*, 1998) MNs displaying a lesion-induced pSTAT3 response (lesion side MNs with nuclear pSTAT3 label much greater than any contralateral MNs; data in Figure 3). With very little contralateral label (e.g., Figure 4), this reliably measured relative pSTAT3 response, particularly given the substantial knockdown effect (Figure 3). This response was not observed outside the area of expected sciatic MNs, further indicating its specificity. MNs were identified by their characteristic location in the ventro-lateral horn and their large nuclei.

The pSTAT3 antiserum has been extensively characterized by western blot (e.g., Starr *et al.*, 1997) and MN immunohistochemistry. *In vivo* CNTF-induced pSTAT3 MN labelling, under the immunohistochemical conditions used here, is: 1) blocked by preabsorption with the antigen peptide but not a non-phosphorylated control or a pseudorandomized phospho-Tyr peptide with the same residues (MacLennan *et al.*, 2000), 2) induced by low picogram quantities of CNTF and leukemia inhibitory factor, which signal through STAT3 Tyr705-

phosphorylation, but not much greater quantities of neurotrophin-3 and brain derived neurotrophic factor, which activate MN phospho-tyrosine-based signaling unrelated to pSTAT3 (MacLennan *et al.*, 2000), and 3) blocked by a specific CNTF receptor antagonist (MacLennan *et al.*, 2000).

Images (Figure 4) captured with a 12 megapixel DXM1200 camera and Nikon E800 microscope with a 10X (NA=0.45) lens were identically adjusted with CorelDRAW.

RESULTS

To specifically deplete muscle CNTFRa we crossed floxed CNTFRa mice (Lee *et al.*, 2008) with mice carrying a Cre recombinase (Cre) gene inserted into the myosin light chain *1f* locus (mlc1f-Cre) (Bothe *et al.*, 2000), a locus expressed very selectively in skeletal muscle cells (Lyons *et al.*, 1990). Mlc1f-Cre excises floxed sequence in all adult skeletal muscles tested, with no excision in brain, spinal cord, sciatic nerve, liver, heart or stomach (Bothe *et al.*, 2000; Lee *et al.*, 2013).

CNTFRa-depleted/knockdown mice (mlc1f-Cre+/-/flxCNTFRa+/+) were compared with non-floxed, littermate controls (mlc1f-Cre+/-/flxCNTFRa-/-). We have shown by semiquantitative PCR that extensor digitorum longus (EDL) muscle CNTFRa expression is increased by sciatic nerve crush and inhibited in the muscle CNTFRa-depleted mice (Lee *et al.,* 2013). Here we used real time PCR to quantitatively compare EDL, soleus and tibialis anterior muscles, which are denervated by the lesion but have different functions and fiber type compositions (Augusto *et al.,* 2004).

All muscles displayed a dramatic lesion-induced increase in CNTFRa expression (Figure 1A-C; tibialis, $F_{1,8}=248.1$, p<0.0001; EDL, $F_{1,8}=133.0$, p<0.0001; soleus, $F_{1,8}=54.4$, p<0.0001) with CNTFRa gene excision greatly reducing CNTFRa expression (Figure 1A-C; tibialis, $F_{1,8}=162.0$, p<0.0001; EDL, $F_{1,8}=979.1$, p<0.0001; soleus, $F_{1,8}=30.72$, p=0.0005). The large but incomplete decrease is consistent with previous mlc1f-Cre work (Bothe *et al.*, 2000) and may result from Cre expression in most but not all the many nuclei in each myofiber.

We also quantified CNTFRa expression in biceps femoris muscle which was longitudinally cut during the nerve crush procedure. It displayed an ~2-fold increase in CNTFRa expression (Figure 2A; $F_{1,10}$ =10.1, p=0.0099). The gene excision again greatly reduced CNTFRa expression (Figure 2A; $F_{1,10}$ =58.2, p<0.0001).

We next determined whether muscle CNTFRa depletion affects the MN STAT3 activation which occurs during the ~2-week period of axon regeneration following sciatic nerve crush (Lee *et al.*, 2004). This activation involves STAT3 Try705 phosphorylation and nuclear translocation (Levy and Darnell, 2002). To track this at a subcellular level *in vivo*, we used an extensively characterized (see Methods) phospho-Tyr705-STAT3-specific antiserum and quantified MNs displaying a lesion-induced increase in nuclear phospho-Try705-STAT3 (see Methods). As previously found (Lee *et al.*, 2004), this pSTAT3 activation was restricted to MNs, like the pSTAT3 response seen after intraparenchymal CNTF injection (MacLennan *et al.*, 2000). The muscle CNTFRa depletion had no effect on MN pSTAT activation at one day

post-lesion (Figure 3; t=0.15, p=0.88, n=7, df=6) but substantially decreased the MN pSTAT3 activation 1 week post-lesion (Figures 3,4; t=7.83, p=0.0014, n=5 df=4).

DISCUSSION

We previously found muscle-specific CNTFRa disruption surprisingly has no effect on muscle itself, but instead impairs MN axon regrowth and motor recovery following nerve lesion (Lee *et al.*, 2013) indicating muscle CNTFRa makes an essential/non-redundant contribution to these functions. Here we show the same muscle CNTFRa depletion decreases lesion-induced MN STAT3 activation. This form of STAT3 activation has been implicated in axon growth (Shin *et al.*, 2012; Pernet *et al.*, 2013; Luo *et al.*, 2016). Therefore, together the data raise the possibility that muscle CNTFRa's promotion of axon regeneration and motor recovery may at least partly result from its contribution to MN STAT3 activation.

Sciatic nerve lesion induces an essentially immediate pSTAT3 increase in lesion site axons that reaches spinal MN nuclei 24 hrs later (Lee *et al.*, 2004) as pSTAT3 acts as a retrograde transcription factor (Ben-Yaakov *et al.*, 2012). While this transient, variable lesion site response does not lend itself to quantification, we did not observe any reliable decrease in it with muscle CNTFRa depletion (data not shown). Although not conclusive, this is consistent with the lack of CNTFRa depletion effect on MN nuclear pSTAT3 1 day postlesion (Figure 3) since the axonal pSTAT3 response, while maximal at 1 day post-lesion, is gone by 3 days post-lesion (Lee *et al.*, 2004). In other words, the data suggest the axonal response contributes to the 1 day post-lesion MN pSTAT3 increase but does not directly contribute to the 1 week post-lesion increase. Here we find muscle CNTFRa depletion does not affect MN STAT3 activation 1 day post-lesion but substantially reduces activation at 1 week (Figure 3). Together the data suggest a rapid pSTAT3 response starting in lesion site axons contributes to an early MN nuclear pSTAT3 increase independent of muscle CNTFRa expression, but a second phase, longer lasting MN nuclear pSTAT3 response is substantially dependent on muscle CNTFRa.

Unconditional knockout work indicates the ligand CNTF is essential for the initial phase of post-lesion MN STAT3 activation but is not required for the second longer lasting phase (Kirsch *et al.*, 2003). It has been suggested that Schwann cell CNTF released by the lesion produces an initial surge of CNTF receptor activation mediating early MN responses (Sendtner *et al.*, 1992b). Therefore, current data suggest two phases of MN STAT3 response with the initial phase at least partly resulting from CNTF activation of STAT3 in lesion site axons leading to the MN nuclei response 1 day post-lesion. This phase is independent of muscle CNTFRa and presumably involves MN expressed CNTFRa. In contrast, the second phase STAT3 response involves muscle CNTFRa and a CNTF receptor ligand other than CNTF. The complex of cardiotrophin-like cytokine/cytokine-like factor-1 (CLC/CLF) also serves as a CNTF receptor ligand (Elson *et al.*, 2000) and may participate in this second phase response. Unfortunately, conditional genetic disruption techniques will need to be developed to address this because complete unconditional knockout of CLF (Elson *et al.*, 2000) or CLC (Zou *et al.*, 2009) leads to perinatal death.

Muscle CNTFRa may promote muscle CNTF receptor signaling leading to release of unidentified muscle factor(s) acting directly or indirectly on MNs to activate STAT3. Moreover, following nerve lesion, muscle CNTFRa is released in a soluble, functional form (Davis *et al.*, 1993b) that could potentially, over time, enhance MN CNTF receptor signaling, including STAT3 activation, by diffusing to regenerating axons for retrograde transport to MN soma, or diffusing directly to the soma. *In vitro* data also suggest muscle CNTFRa is released as a CNTFRa/CLC complex able to activate CNTF receptor signaling including STAT3 (Plun-Favreau et al , 2001).

The separation between the mid-thigh lesion and lower limb denervated muscles may seem to argue against factors from these muscles acting directly on axotomized MNs. However, the rapid, dramatic increase in muscle CNTFRa expression is sustained for at least 10 days (Helgran *et al.*, 1994) suggesting CNTFRa and/or CNTFRa-dependent factors from denervated muscles could act on MNs, particularly with several days to diffuse to regenerating axons and contribute to the second phase of STAT3 activation.

The CNTFRa qRT-PCR data suggest a wide variety of denervated muscles are involved. They also identify, for the first time, the damaged lesion site muscle as another potential source of CNTFRa contributing to MN STAT3 activation and the muscle CNTFRadependent axon regeneration and motor recovery (Lee *et al.*, 2013). This muscle is analogous to lesion site muscle invariably damaged clinically with accidental nerve lesion. Although the CNTFRa expression is much less than in denervated muscles (Figure 2B), the damage-induced increase in expression, and the muscles' close proximity to the crushed axons, both suggest it may participate.

While CNTFRa depletion substantially reduces the second phase of MN STAT3 activation it does not eliminate it. The activation may be completely dependent on muscle CNTFRa with the remaining 20% of muscle CNTFRa expression sustaining the STAT3 activation observed. Alternatively, CNTFRa expressed by MNs may contribute, as could other STAT3-signaling receptor types.

Sciatic nerve lesion also increases pSTAT3 in dorsal root ganglion neurons (Lee *et al.,* 2004). Unfortunately, we were unable to establish a quantitative assay for mouse dorsal root ganglion pSTAT3 (likely due to variability in fix, antibody penetration, etc. with such small tissues). However, it certainly remains possible that muscle CNTFRa contributes to this pSTAT3 activation.

The present data and our previous work (Lee *et al.*, 2013) suggest muscle CNTFRa. upregulation promotes MN regeneration by indirectly regulating MN signaling. Therefore, enhancing muscle CNTFRa expression may be worth considering as a therapeutic to promote MN regeneration in trauma and disease. In contrast to MN gene expression, skeletal muscle gene expression can be enhanced in humans with gene therapy techniques currently approved for market (Ylä-Herttuala, 2012).

Acknowledgements:

Supported by NIH grants NS35224 and NS052700 to A.J.M.

Abbreviations:

CLC	cardiotrophin-like cytokine
CLF	cytokine-like factor-1
CNTF	ciliary neurotrophic factor
CNTFRa	ciliary neurotrophic factor receptor a
Cre	Cre recombinase
EDL	extensor digitorum longus
flxCNTFRa	floxed CNTFRa gene
LIFRβ	leukemia inhibitory factor receptor β
MN	motor neuron
PFA	paraformaldehyde
pSTAT3	phospho-Tyr705 STAT3
STAT3	signal transducer and activator of transcription 3
qRT-PCR	quantitative real-time PCR

References

- Augusto V, Padovani CR & Campos GER (2004) Skeletal muscle fiber types in C57BL6J mice. Braz. J. Morphol. Sci, 21(2), 89–94.
- Ben-Yaakov K, Dagan SY, Segal-Ruder Y, Shalem O, Vuppalanchi D, Willis DE, Yudin D, Rishal I, Rother F, Bader M, Blesch A, Pilpel Y, Twiss JL & Fainzilber M (2012) Axonal transcription factors signal retrogradely in lesioned peripheral nerve. EMBO J, 3 21;31(6), 1350–1363. [PubMed: 22246183]
- Bothe GWM, Haspel JA, Smith CL, Wiener HH & Burden SJ (2000) Selective expression of Cre recombinase in skeletal muscle fibers. Genesis, 26, 165–166. [PubMed: 10686620]
- Davis S, Aldrich TH, Stahl N, Pan L, Taga T, Kishimoto T, Ip NY & Yancopoulos GD (1993a) LIFRβ and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science, 260, 1805–1808. [PubMed: 8390097]
- Davis S, Aldrich TH, Ip NY, Stahl N, Scherer S, Farruggella T, DiStefano PS, Curtis R, Panayotatos N, Gascan H, Chevalier S & Yancopoulos GD (1993b) Released form of CNTF receptor a component is a soluble mediator of CNTF responses. Science, 259, 1736–1739. [PubMed: 7681218]

DeChiara TM, Vejsada R, Poueymirou WT, Acheson A, Suri C, Conover JC, Friedman B, McClain J, Pan L, Stahl N, Ip NY, Kato A & Yancopoulos GD (1995) Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth. Cell, 83, 313–322. [PubMed: 7585948]

- Elson GCA, Lelievre E, Guillet C, Chevalier S, Plun-Favreau H, Froger J, Suard I, Benoit de Coignac A, Delneste Y, Bonnefoy J–Y, Gauchat J-F & Gascan H (2000) CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nature Neurosci, 3, 867–872. [PubMed: 10966616]
- Helgren ME, Squinto SP, Davis HL, Parry DJ, Boulton TG, Heck CS, Zhu Y, Yancopoulos GD, Lindsay RM & DiStefano PS (1994) Trophic effect of ciliary neurotrophic factor on denervated skeletal muscle. Cell, 76, 493–504. [PubMed: 8313470]

- Hyman BT, Gomez-Isla T & Irizarry MC (1998) Stereology: A practical primer for neuropathology. J. Neuropath. Exp. Neurol, 57, 305–310. [PubMed: 9600222]
- Janjua MZ & Leong SK (1984) Organization of neurons forming the femoral, sciatic, common peroneal and tibial nerves in rats and monkeys. Brain Res, 310, 311–323. [PubMed: 6488022]
- Kirsch M, Terheggen U & Hofmann HD (2003) Ciliary neurotrophic factor is an early lesion-induced retrograde signal for axotomized facial motoneurons. Mol. Cell. Neurosci, 24(1), 130–8. [PubMed: 14550774]
- Lee MY, Hofmann HD & Kirsch M (1997) Expression of ciliary neurotrophic factor receptor-alpha messenger RNA in neonatal and adult rat brain: an in situ hybridization study. Neurosci, 77, 233–246.
- Lee N, Neitzel KL, Devlin BK & MacLennan AJ (2004) STAT3 phosphorylation in injured axons before sensory and motor neuron nuclei: potential role for STAT3 as a retrograde signaling transcription factor. J. Comp. Neurol, 7 5;474(4), 535–45. [PubMed: 15174071]
- Lee N, Robitz R, Zurbrugg RJ, Karpman AM, Mahler AM, Cronier SA, Vesey R, Spearry RP, Zolotukhin S & MacLennan AJ (2008) Conditional, genetic disruption of ciliary neurotrophic factor receptors reveals a role in adult MN survival. Eur. J. Neurosci, 27, 2830–2837. [PubMed: 18588528]
- Lee N, Spearry RP, Leahy KM, Robitz R, Trinh DS, Mason CO, Zurbrugg RJ, Batt MK, Paul RJ & MacLennan AJ (2013) Muscle ciliary neurotrophic factor receptor a promotes axonal regeneration and functional recovery following peripheral nerve lesion. J. Comp. Neurol, 521(13), 2947–2965. [PubMed: 23504871]
- Levy DE & Darnell JE (2002) STATS: transcriptional control and biological impact. Nature Rev, 3, 651–662.
- Luo X, Ribeiro M, Bray ER, Lee DH, Yungher BJ, Mehta ST, Thakor KA, Diaz F, Lee JK, Moraes CT, Bixby JL, Lemmon VP & Park KK (2016) Enhanced Transcriptional Activity and Mitochondrial Localization of STAT3 Co-induce Axon Regrowth in the Adult Central Nervous System. Cell Rep, 15(2), 398–410. [PubMed: 27050520]
- Lyons GE, Ontell M, Cox R, Sassoon D & Buckingham M (1990) The expression of myosin genes in developing skeletal muscle in the mouse embryo. J. Cell. Biol, 111, 1465–1476. [PubMed: 2211821]
- MacLennan AJ, Vinson EN, Marks L, McLaurin DL, Pfeifer M & Lee N (1996) Immunohistochemical localization of ciliary neurotrophic factor receptor α expression in the rat nervous system. J. Neurosci, 16, 621–630. [PubMed: 8551346]
- MacLennan AJ, Devlin BK, Neitzel KL, McLaurin DL, Anderson KJ & Lee N (1999) Regulation of ciliary neurotrophic factor receptor alpha in sciatic MNs following axotomy. Neuroscience, 91(4), 1401–1413. [PubMed: 10391446]
- MacLennan AJ, Neitzel KL, Devlin BK, Garcia J, Hauptman GA, Gloaguen I, Di Marco A, Laufer R & Lee N (2000) In vivo localization and characterization of functional ciliary neurotrophic factor receptors which utilize JAK-STAT signaling. Neuroscience, 99(4), 761–72. [PubMed: 10974439]
- Pernet V, Joly S, Jordi N, Dalkara D, Guzik-Kornacka A, Flannery JG & Schwab ME (2013) Misguidance and modulation of axonal regeneration by Stat3 and Rho/ROCK signaling in the transparent optic nerve. Cell Death Dis, 18;4:e734.
- Plun-Favreau H, Elson G, Chabbert M, Froger J, deLapeyrière O, Lelièvre E, Guillet C, Hermann J, Gauchat JF, Gascan H & Chevalier S (2001) The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine. EMBO J, 20(7), 1692–703. [PubMed: 11285233]
- Sahenk Z, Seharaseyon J & Mendell JR (1994) CNTF potentiates peripheral nerve regeneration. Brain Res, 655, 246–250. [PubMed: 7812780]
- Sendtner M, Stockli KA & Thoenen H (1992b) Synthesis and localization of ciliary neurotrophic factor in the sciatic nerve of the adult rat after lesion and during regeneration. J Cell Biol, 118, 139–148. [PubMed: 1618901]
- Shin JE, Cho Y, Beirowski B, Milbrandt J, Cavalli V & DiAntonio A (2012) Dual leucine zipper kinase is required for retrograde injury signaling and axonal regeneration. Neuron, 74(6):1015–22. [PubMed: 22726832]

- Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA & Hilton DJ (1997) A family of cytokine-inducible inhibitors of signalling. Nature, 387, 917–921. [PubMed: 9202125]
- Ylä-Herttuala S (2012) Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol. Ther, 20(10), 1831–2. [PubMed: 23023051]
- Zou X,Bolon B, Pretorius JK, Kurahara C, McCabe J, Christiansen KA, Sun N, Duryea D, Foreman O, Senaldi G, Itano AA & Siu G (2009) Neonatal death in mice lacking cardiotrophin-like cytokine is associated with multifocal neuronal hypoplasia. Vet. Pathol, 46(3):514–9. [PubMed: 19098279]

Author Manuscript

Author Manuscript



Figure 1. Muscle CNTFRa gene disruption greatly reduces CNTFRa expression in a wide range of denervated muscles.

CNTFRa knockdown and littermate controls received a unilateral sciatic nerve crush. Twenty-four hours later, ipsilateral and contralateral tibialis anterior (**A**), EDL (**B**), and soleus (**C**) muscles were dissected for CNTFRa qRT-PCR. n=3/condition. All lesion and knockdown effects were significant (P<0.0005; text for statistics).



Figure 2. CNTFRa is induced in muscle damaged at the lesion site. Muscle CNTFRa knockdown and littermate controls received a unilateral sciatic nerve crush. Twenty-four hours later biceps femoris muscles ipsilateral and contralateral to the lesion were dissected. CNTFRa RNA, quantified by qRT-PCR, is presented relative to control mouse intact side biceps femoris (A) and denervated muscles (B). Biceps femoris damage increases CNTFRa expression (p=0.0099) which is reduced by the knockdown (p<0.0001). n=4 knockdown, 3 controls.



Figure 3. Muscle CNTFRa knockdown selectively reduces the second phase of lesion-induced STAT3 activation in motor neurons.

Muscle CNTFRa knockdown and littermate controls received a unilateral sciatic nerve crush. MNs with a lesion-induced pSTAT3 response were immunohistochemically quantified. The knockdown had no effect on STAT3 activation one day post-lesion (p=0.88, n=7), but substantially reduced activation one week post-lesion (**p=0.0014, n=5).



Figure 4. pSTAT3 immunohistochemistry examples.

Spinal cord ventral horns from control (**A**,**B**) and CNTFRa knockdown (**C**,**D**) mice 1 week post-lesion. Lesion on right (**B**,**D**); dorsal to top. The lesion-induced increase in MN nuclear pSTAT3 label was smaller with CNTFRa knockdown. Broken lines=grey matter borders not otherwise apparent since signal is highly specific to pSTAT3. Scale bar=100µm.